Definiens AG, a Munich, Germany-based provider of image analysis technology for digital pathology, has raised €10m (approximately $12.8m) in funding.
The round was led by Gilde Healthcare Partners, with participation from existing investors TVM, Cipio and Definiens’ management.
The company intends to use the funding for commercial expansion of its current business and to develop and commercialize innovative products for Clinical Digital Pathology.
Founded by CTO and Nobel Laureate Prof Dr Gerd Binnig and led by Thomas Heydler, CEO, Definiens has developed Cognition Network Technology® that enables analysis of Digital Pathology images, and other types of images.
The company’s solutions are currently being used for research and development by all major pharmaceutical companies as well as an increasing number of diagnostic companies in tissue based diagnostic biomarker development.
In conjunction with the investment, Dr Janke Dittmer, partner at Gilde Healthcare Partners, has joined Definiens’ Supervisory Board.